Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, at 8:30 AM Pacific Standard Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=20209. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
